How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.
Similar Posts
Clinical trials for medicines: manage your authorisation, report safety issues
Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report.
MHRA Safety Roundup: October 2025
Summary of the latest safety advice for medicines and medical device users
Decision: Advertising Investigations: May 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
New MHRA-supported research reveals patterns of vaccine-derived poliovirus spread and implications for global eradication efforts
Study provides crucial insights for targeting rapid response strategies and improving polio surveillance worldwide
MHRA approves nogapendekin alfa inbakicept to treat adult patients with non-muscle invasive bladder cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 4 July 2025, approved nogapendekin alfa inbakicept (Anktiva) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where the disease remains confined to the inner lining of the bladder and may include tumours.
Guidance: Medicines that you cannot export from the UK or hoard
Sets out medicines that cannot be exported from the UK or hoarded because they are needed for UK patients.